Skip Navigation



JAC Advance Access published online on May 9, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki140
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/6/1016    most recent
dki140v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gil-Lamaignere, C.
Right arrow Articles by Müller, F.-M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gil-Lamaignere, C.
Right arrow Articles by Müller, F.-M. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
Received November 23, 2004
Revised March 5, 2005
Accepted March 31, 2005

Brief report

Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes

Cristina Gil-Lamaignere 1, Regina Hess 1, Stefanie Salvenmoser 1, Kathrin Heyn 1, Reinhard Kappe 2, and Frank-Michael C. Müller 1*

1 Department of Paediatrics III, Paediatric Pulmonology and Infectious Diseases, University of Heidelberg, Im Neuenheimer Feld 153, D-69120 Heidelberg, Germany
2 Haema Institute of Laboratory Medicine at the Helios Medical Center, Erfurt, Germany

* To whom correspondence should be addressed.
Frank-Michael C. Müller, E-mail: Frank-Michael_Mueller{at}med.uni-heidelberg.de


  Abstract

Objectives: The effect of different media and composition on the in vitro activity of posaconazole, caspofungin and voriconazole against 59 zygomycetes species was determined.

Methods: The media tested were RPMI 1640 medium with and without 2% glucose, antibiotic medium 3 (AM3) with and without 2% glucose, and high resolution (HR) medium.

Results: Posaconazole was significantly more active than caspofungin and voriconazole, both in RPMI 1640 medium with 2% glucose and in HR medium. Adding glucose improved the determination of end points, but had only minor influence on the MICs. MICs evaluated in AM3 were lower than in RPMI 1640 medium or HR medium.

Conclusions: The in vivo effect of posaconazole in zygomycosis needs further evaluation.

Keywords: rhizopus; mucor; absidia; rhizomucor; cunninghamella.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. Torres-Narbona, J. Guinea, J. Martinez-Alarcon, T. Pelaez, and E. Bouza
In Vitro Activities of Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole against 45 Clinical Isolates of Zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1126 - 1129.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Sabatelli, R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas
In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2009 - 2015.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. Antachopoulos, J. Meletiadis, E. Roilides, T. Sein, and T. J. Walsh
Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay
J. Clin. Microbiol., February 1, 2006; 44(2): 553 - 560.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.